This technology provides a method for monitoring cellular death in radiotherapy patients using low-frequency ultrasound. It combines conventional frequency (5-10 MHz) ultrasound with new software to detect responses to radiotherapy in breast cancer tissues.
Inventor
Status Under license to a global therapy provider.